Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis

Open access
Mincu, Raluca I., Mahabadi, Amir A., Michel, Lars, Mrotzek, Simone M., Schadendorf, Dirk, Rassaf, Tienush, Totzeck, Matthias·2019·JAMA Network Open

Abstract

Importance: Cardiovascular adverse events (CVAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. Objective: To determine the association of BRAF and MEK inhibitor treatment with CVAEs in patients with melanoma compared with BRAF inhibitor monotherapy. Data Sources: PubMed, Cochrane, and Web of Science were systematically searched for keywords vemurafenib, dabrafenib, encorafenib, trametinib, binimetinib, and cobinimetinib from database inception through November 30, 2018. Study Selection: Randomized clinical trials reporting on CVAEs in patients with melanoma being treated with BRAF and MEK inhibitors compared with patients with melanoma being treated with BRAF inhibitor monotherapy were selected. Data Extraction and Synthesis: Data assessment followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. Pooled relative risks (RRs) and 95% CIs were determined using random-effects and fixed-effects analyses. Subgroup analyses were conducted to assess study-level characteristics associated with CVAEs. Main Outcomes and Measures: The selected end points were pulmonary embolism, a decrease in left ventricular ejection fraction, arterial hypertension, myocardial infarction, atrial fibrillation, and QTc interval prolongation. All-grade and high-grade (≥3) CVAEs were recorded. Results: Overall, 5 randomized clinical trials including 2317 patients with melanoma were selected. Treatment with BRAF and MEK inhibitors was associated with an increased risk of pulmonary embolism (RR, 4.36; 95% CI, 1.23-15.44; P = .02), a decrease in left ventricular ejection fraction (RR, 3.72; 95% CI, 1.74-7.94; P < .001), and arterial hypertension (RR, 1.49; 95% CI, 1.12-1.97; P = .005) compared with BRAF inhibitor monotherapy. The RRs for myocardial infarction, atrial fibrillation, and QTc prolongation were similar between the groups. These results were consistent when assessing high-grade CVAEs (left ventricular ejection fraction: RR, 2.79; 95% CI, 1.36-5.73; P = .005; I2 = 29%; high-grade arterial hypertension: RR, 1.54; 95% CI, 1.14-2.08; P = .005; I2 = 0%), but RRs for high-grade pulmonary embolism were similar between groups. A higher risk of a decrease in left ventricular ejection fraction was associated with patients with a mean age younger than 55 years (RR, 26.50; 95% CI, 3.58-196.10; P = .001), and the associated risk of pulmonary embolism was higher for patients with a mean follow-up time longer than 15 months (RR, 7.70; 95% CI, 1.40-42.12; P = .02). Conclusions and Relevance: Therapy with BRAF and MEK inhibitors was associated with a higher risk of CVAEs compared with BRAF inhibitor monotherapy. The findings may help to balance between beneficial melanoma treatment and cardiovascular morbidity and mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2019.8890

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 36

  1. Schadendorf, 2018, Melanoma., Lancet, 392, 971, 10.1016/S0140-6736(18)31559-9 · DOI · Paper page
  2. Bronte, 2015, What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment., Oncotarget, 6, 35589, 10.18632/oncotarget.v6i34 · doi:10.18632/oncotarget.v6i34
  3. Schadendorf, 2017, Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials., Eur J Cancer, 82, 45, 10.1016/j.ejca.2017.05.033 · DOI · Paper page
  4. Solit, 2011, Resistance to BRAF inhibition in melanomas., N Engl J Med, 364, 772, 10.1056/NEJMcibr1013704 · DOI · Paper page
  5. Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib., N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 · DOI · Paper page
  6. Dummer, 2018, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 19, 1315, 10.1016/S1470-2045(18)30497-2 · DOI · Paper page
  7. Long, 2017, Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma., N Engl J Med, 377, 1813, 10.1056/NEJMoa1708539 · DOI · Paper page
  8. Long, 2017, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study., Ann Oncol, 28, 1631, 10.1093/annonc/mdx176 · DOI · Paper page
  9. Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial., Lancet Oncol, 17, 1248, 10.1016/S1470-2045(16)30122-X · DOI · Paper page
  10. Hauschild, Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma., J Clin Oncol
  11. Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
  12. Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
  13. Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma., N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
  14. Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI · Paper page
  15. Livingstone, 2014, BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management., Chin Clin Oncol, 3, 29
  16. Banks, 2017, Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism., Cardiovasc Toxicol, 17, 487, 10.1007/s12012-017-9425-z · doi:10.1007/s12012-017-9425-z
  17. Kubin, 2017, The MEK1 inhibitors UO126 and PD98059 block PDGF-AB induced phosphorylation of threonine 292 in porcine smooth muscle cells., Cytokine, 95, 51, 10.1016/j.cyto.2017.02.003 · DOI
  18. Liu, 2017, BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma., Oncotarget, 8, 69477, 10.18632/oncotarget.17704 · DOI
  19. Rose, 2010, Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale., Physiol Rev, 90, 1507, 10.1152/physrev.00054.2009 · DOI · Paper page
  20. Viera, 2008, Odds ratios and risk ratios: what’s the difference and why does it matter?, South Med J, 101, 730, 10.1097/SMJ.0b013e31817a7ee4 · DOI · Paper page
  21. Zhu, 2017, Increased apoptosis in the paraventricular nucleus mediated by AT1R/Ras/ERK1/2 signaling results in sympathetic hyperactivity and renovascular hypertension in rats after kidney injury., Front Physiol, 8, 41, 10.3389/fphys.2017.00041 · DOI
  22. Bronte, 2015, Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy., Expert Opin Drug Saf, 14, 253, 10.1517/14740338.2015.986092 · DOI
  23. Rassaf, 2003, NO adducts in mammalian red blood cells: too much or too little?, Nat Med, 9, 481, 10.1038/nm0503-481 · DOI
  24. Abdel-Rahman, 2016, Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data., Clin Transl Oncol, 18, 848, 10.1007/s12094-015-1438-0 · DOI
  25. Liu, 2017, Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials., Oncotarget, 8, 32258, 10.18632/oncotarget.15632 · DOI
  26. Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC., Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128 · DOI · Paper page
  27. Larkin, 2014, Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study., Lancet Oncol, 15, 436, 10.1016/S1470-2045(14)70051-8 · DOI · Paper page
  28. Ascierto, 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol, 31, 3205, 10.1200/JCO.2013.49.8691 · DOI · Paper page
  29. Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial., Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 · DOI · Paper page
  30. Chapman, 2017, Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study., Ann Oncol, 28, 2581, 10.1093/annonc/mdx339 · DOI · Paper page
  31. Maio, 2018, Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial., Lancet Oncol, 19, 510, 10.1016/S1470-2045(18)30106-2 · DOI · Paper page
  32. Zamorano, 2016, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)., Eur Heart J, 37, 2768, 10.1093/eurheartj/ehw211 · DOI · Paper page
  33. Totzeck, 2019, Cardio-oncology: strategies for management of cancer-therapy related cardiovascular disease., Int J Cardiol, 280, 163, 10.1016/j.ijcard.2019.01.038 · DOI · Paper page
  34. Welsh, 2015, Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma., Ther Adv Med Oncol, 7, 122, 10.1177/1758834014566428 · DOI · Paper page
  35. Knispel, 2018, The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma., Expert Opin Drug Saf, 17, 73, 10.1080/14740338.2018.1390562 · DOI
  36. HigginsJPT, GreenD. Cochrane Handbook for Systematic Reviews of Interventions. http://handbook-5-1.cochrane.org/. Accessed June 27, 2019. · DOI · Paper page

Cited by

See all 170

Metadata

Authors
Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M.
Venue
JAMA Network Open
Published
2019-08-09
Volume
2
Issue
8
Pages
e198890
ISSN
2574-3805 (ISSN-L)
OpenAlex
W2968344727
Cited by
170
References
6
FWCI
4.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2019.8890
The paper
Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M. (2019). Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2019.8890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.